Paydirt
CC
Insider

Charles Cherington

10% owner

Charles Cherington (10% owner) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales, 1 filed past the two-business-day deadline), most often in ERNA. Across 1 priced purchase filing, the average 21-session return was -9.4% from execution and -23.7% from disclosure (delay-adjusted; derived). The largest single filing was $2.0M of ERNA (4,000,000 sh × $0.50, as filed), executed Feb 10.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
-9.4%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-23.7%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells · 1 late
Median delay
7d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$2.0M
shares × price, as filed
Last traded
Feb 10
Filed Feb 17
Open performance→
Volume by month
$2.0M$1.0M$0Oct 2024Apr 2025Oct 2025Apr 2026Feb 2026 · buys $2.0M
Buys $2.0M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Not on file 1 filing

Sector per market data · by filing · past 12 months

Most traded names
ERNA ERNA ERNA · 5 buys · 0 sells 5 filings
Recent filings
ERNAPURCHASE Ernexa Therapeutics Inc. View filing → $2.0M
4,000,000 sh × $0.50
Exec Feb 10
Filed Feb 17 · 9:14 PM ET † ERNAPURCHASE Ernexa Therapeutics Inc. View filing → –
21,241,163 sh · price not plausible
Exec Jun 9 2025
Filed Jun 11 2025 · 5:30 PM ET ERNAPURCHASE Eterna Therapeutics Inc. View filing → –
3,768,397 sh · price not plausible
Exec Apr 2 2025
Filed Apr 4 2025 · 5:30 PM ET ERNAPURCHASE Eterna Therapeutics Inc. View filing → –
13,252,112 sh across 5 lots · price not plausible
Exec Oct 29 2024
Filed Nov 5 2024 · 5:30 PM ET † ERNAPURCHASE Ernexa Therapeutics Inc. View filing → –
13,252,112 sh across 5 lots · price not plausible
Exec Sep 24 2024
Filed May 7 2025 · 5:30 PM ET †